Our purpose was to assess efficacy and toxicity of highdose chemotherapy (HDCT) and ASCT in patients with relapsed and refractory Hodgkin's lymphoma (HL) aged 60 years and older and compare the results with a group of younger HL patients treated in a similar manner. We identified 15 consecutive patients, with HL aged 60 years and older who underwent HDCT (etoposide 60 mg/kg þ melphalan 160 mg/m 2 ) and ASCT at our institution from May 2001 to March 2008. The results were compared with a cohort of 157 younger HL patients treated in a similar manner from January 1999 to December 2006. After a median follow-up of 2.5 years, PFS at 3 years after ASCT was 73% (95% confidence interval (CI) 37-90) for the older group and 56% (95% CI 46-64) for the younger group (P ¼ 0.45); OS after ASCT was 88% (95% CI 39-98) for the older group and 84% (95% CI 75-90) for the younger group (P ¼ 0.80). No transplantrelated deaths were seen. Our study suggests that ASCT is feasible for selected elderly patients with HL, giving similar results to younger patients in terms of survival and toxicity.
Introduction
Within population-based studies, the proportion of Hodgkin's lymphoma (HL) patients older than 60 years at diagnosis ranges between 20 and 44%. 1, 2 Several studies have reported a worse outcome for patients with HL aged 50-65 years compared with younger patients when similar treatments were given. [3] [4] [5] Older patients present more frequently with adverse prognostic factors, including mixed cellularity histology, B symptoms and poor performance status, and experience greater hematological toxicity and reduced delivery of standard induction therapy. 6 Survival in elderly patients with HL has been reported to be improving at a greater rate than in younger patients in recent years, but relative survival is still significantly inferior for those aged more than 60 years. 7 In advanced HL, improved 5-year failure-free survival has been reported with newer multidrug chemotherapy regimens. [8] [9] [10] However, in a randomized study carried out by the German Hodgkin Study Group, there was no difference in treatment outcome or OS between baseline BEACOPP and standard COPP-ABVD, when used in elderly patients. 11 Furthermore, more acute toxicity and treatment-related deaths (21%) were observed in patients treated with baseline BEACOPP.
The use of high-dose chemotherapy (HDCT) and ASCT as second-line therapy in patients with HL is supported by two randomized clinical trials showing improved disease-free survival. 12, 13 None of the trial included patients aged 60 years or older. However, a number of recent studies have demonstrated that ASCT can be carried out in older patients with non-Hodgkin's lymphomas (NHL) and multiple myeloma, with acceptable toxicity and minimal TRM. [14] [15] [16] We analyzed the efficacy and feasibility of HDCT and ASCT in a group of patients with relapsed (REL) and refractory (REF) HL aged 60 years and older. The results were compared with a cohort of younger patients treated in a similar manner at our institution. Patients received etoposide (60 mg/kg i.v. over 8 h on day À4) and melphalan (180 mg/m 2 i.v. over 30 min on day À3) as HDCT. Stem cells were infused on day 0. Supportive care was provided as described previously. 18 Involved field radiation (35 Gy in 20 fractions) was administered to patients with bulky disease 45 cm at the time of disease progression/recurrence, generally between 6 and 12 weeks after receiving HDCT. Routinely, re-staging was performed as above, at 3 months and 1 year after ASCT. Patients presenting with signs or symptoms suggestive of relapse or progression underwent appropriate work-up as required.
Patients and methods

Patients
Statistical methods
This cohort was divided into two groups on the basis of the age at transplant: a young group, aged o60 years and an old group, aged X60 years. The clinical characteristics of these two groups were compared using either Fisher's exact test, when the covariate was categorical, or Wilcoxon rank-sum test, when the covariate was continuous. To match the two populations, we calculated the propensity score using the age group as outcome and gender, REF vs REL, extranodal disease at diagnosis, first-line treatment (chemotherapy vs combined modality therapy), response to first-line treatment (CR þ PR vs stable/progressive disease), stage and B symptoms at relapse as explanatory variables. Survival times were calculated from the date of ASCT to death or last follow-up. Time to progression was calculated from the date of ASCT to progression, death or date of last follow-up. The estimates for OS and PFS were calculated using Kaplan-Meier methods and the comparisons between different distributions were done using log-rank test.
Results
Response to salvage chemotherapy The characteristics of the two patient groups are listed in Table 1 . The overall response rate to second-line chemotherapy (CR þ CRu þ PR) was 73% (98/137) for the younger group, including 26 CRs and 93% (14/15) for the older group, including three CRs. A total of 28 patients in the younger group (21%) and one patient on the older group (7%) had SD. Eight patients, all of them in the younger group, achieved a PR after further salvage chemotherapy (mini-BEAM in five) and proceeded to ASCT.
Stem cell mobilization and leukapheresis
The median number of leukapheresis procedures required to obtain an adequate PBSC collection for transplantation was two (range, 1-4) in the older group and one (range, [1] [2] [3] [4] [5] in the younger group (P ¼ 0.029). The proportion of patients who had PBSC collections greater than the threshold of 2 Â 10 6 CD34 þ cells/kg was 93% in the older group and 94% in the younger group (P40.99), whereas the proportion of patients in whom the same threshold could be reached after a single apheresis procedure was 64% in the older group and 83% in the younger group (P ¼ 0.14). The median number of stem cells collected was significantly lower in the elderly group compared with the younger cohort (5.0 vs 7.6 Â 10 6 CD34 þ cells/kg, P ¼ 0.015) Autologous BM harvest was necessary in 2 patients in the older group (13%) and in 10 patients in the younger group (7%, P ¼ 0.34).
Hematopoietic engraftment
The median time to achieve neutrophils 40.5 Â 10 9 /L. was 11 days (range, 9-22) in the older group and 11 days (range, 9-25) in the younger group (P ¼ 0.35, Table 2 ). The median time to achieve unsupported plts 420 Â 10 9 /L was 13 days (range, 9-43) in the older group and 11 days (range, 0X120) in the younger group (P ¼ 0.016). Median number of packed RBC transfused was three (range, 0-6) in the older group and two (range, 0-8) in the younger group (P ¼ 0.70). Median number of platelet transfusions was two (range, 1-10) in the older group and one (range, 0-14) in the younger cohort (P ¼ 0.044).
Toxicity
Neutropenic fever (438 1C) following HDCT was observed in 98 patients; 85 (75%) in the younger cohort and 13 (81%) in the older cohort. Median duration of i.v.
antibiotic treatment was 4 days (range, 0-14) in the older group and 6 days (range, 0-28) in the younger group (P ¼ 0.78). Non-hematological toxicity is summarized in Table 3 . Median days of hospitalization following stem cell infusion were 14 (range, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in the older group and 13 (range, 10-40) in the younger group (P ¼ 0.11).
Post-transplant outcomes
After a median follow-up of 2.5 years for both groups, OS after ASCT was 88% (95% confidence interval (CI) 39-98) for the older group and 84% (95% CI 75-90) for the younger group (P ¼ 0.80) (Figure 1 ). PFS at 3 years after ASCT was 73% (95% CI 37-90) for the older group and 56% (95% CI 46-64) for the younger group (P ¼ 0.45) (Figure 2) . No transplant-related deaths were seen. A total of 52 (38%) patients in the younger group and 3 (20%) in the older group were found to have progressive disease within 3 years after transplant. For survival, the hazard ratio for the age group alone in the Cox model was 1.3 (P ¼ 0.8); when the propensity scores were included, the hazard ratio increased to 1.8 (P ¼ 0.6). For PFS, the hazard ratio increased from 1.56 (P ¼ 0.5), when age was alone in the model, to 1.66 (P ¼ 0.4) when the propensity scores were included.
Discussion
Although not associated with a clear survival benefit over standard-dose therapy, HDCT and ASCT is currently considered the standard of care for patients with REL or REF HL. 12, 13 Though elderly patients were excluded from earlier trials, our study suggests that ASCT is feasible for ASCT in elderly patients with Hodgkin's lymphoma N Puig et al selected older patients with HL and gives results similar to younger patients, in terms of disease-free survival, OS and toxicity. The different median age of the elderly group (64 years) compared with the younger cohort (36 years) reflects both the selection criteria used at our center, restricted only to the 'younger old', as well as the young median age of the HL patient population in general. Importantly, after matching the two cohorts, we confirmed that the similar outcome of these two populations could not be explained by differences in treatment strategies or prognostic variables at initiation of second-line therapy.
To date, there have been no randomized studies evaluating the toxicity and efficacy of ASCT in elderly patients with recurrent or REF lymphoma. There are several reports of single center and transplant registry experience, but these have predominantly focused on non-Hodgkin's lymphomas (NHL), with very few describing the outcome of patients with HL. [19] [20] [21] [22] [23] [24] [25] [26] [27] These studies have shown that ASCT is feasible in selected NHL patients over the age of 60 years. Early treatment-related mortality was reported to be 5-10%, higher than is observed in patients aged less then 60 years with NHL. Treatment-related mortality in our small series compares favorably with earlier reports of outcome in this age group, possibly because of the use of PBSCs instead of BM, and patient selection.
In terms of efficacy, one retrospective comparison suggested that PFS in elderly patients (age 465 years) with NHL is similar to younger patients treated with ASCT in chemo-sensitive relapse. 26 In a similar study, Buadi et al. 27 found no differences in EFS after transplant between the two groups, although OS was significantly lower in the elderly group.These authors found that more patients in the younger group died with progressive disease (59/178, 86% vs 33/93, 25%). 27 In contrast, a recent large series of patients (n ¼ 2612) with diffuse large B-cell lymphoma, reported to the EBMTR, showed a higher treatment-related mortality at day 100, and at 1 and 3 years for patients aged 460 years receiving ASCT, compared with younger patients. Relapse rate, disease-free survival and OS were significantly inferior for the older patient cohort, reflecting the known adverse effect of age on treatment outcome in aggressive histology lymphoma. 28 A similarly powered study in HL has not been reported to date.
In our study, a similar proportion of patients within both groups achieved PBSC collections greater than the threshold of 2 Â 10 6 CD34 þ cells/kg. However, elderly patients required a higher number leukapheresis to do so and the median number of stem cells collected was also significantly lower in this group. Whereas there were no differences in the median days to neutrophil engraftment between both groups, time to plt engraftment was slightly longer in the older patients. This resulted in higher transfusion requirements, but did not result in a higher rate of serious or lifethreatening bleeding (data not shown). Previous smaller cohort trials have not shown a difference in the rate of plt recovery to 420 Â 10 9 cells/L, though complete plt recovery may be slower. 29, 30 Despite the differences found between the two groups, hospital stay and median days of antibiotics were similar. As shown in our study and by other groups, PBSC collection is feasible in elderly patients. 20, 22, 24, 25 However, there is also increasing evidence that aging affects the proliferative potential of hematopoietic stem cells, which could explain the age-related differences in mobilization and plt recovery that we observed. 29 The number of elderly HL patients included in our study is small and is likely a reflection of the rarity of this condition (incidence 2-4/100 000 per year) together with its predilection for younger adults. As well, referral bias and patient selection might have significantly influenced our results, but the same inclusion criteria with regard to chemotherapy sensitivity and organ function were applied to both cohorts. A total of 4 out of the 19 patients aged 60 years and older referred to our institution for consideration of HDCT and ASCT between 2001 and 2008 did not proceed with the transplant (because of comorbidities, age 465 years at referral, lack of response to chemotherapy and patient decision). Although the follow-up of the elderly cohort is still short, to date only three patients have relapsed, whereas 96% of relapses (56 of 58) observed within the younger cohort occurred within the three first years after transplant. More follow-up and additional patients are required to determine the long-term benefit of ASCT in elderly patients with REL HL. ASCT in elderly patients with Hodgkin's lymphoma N Puig et al
In conclusion, this study is the first to our knowledge to focus on elderly patients with REL and REF HL, and suggests that HDCT and ASCT can be performed in selected elderly patients with acceptable outcome and toxicity. Additional studies focusing on the impact of comorbidities on patient selection and outcome appear warranted.
